Feasibility and preliminary efficacy of the 'HEYMAN' healthy lifestyle program for young men: a pilot randomised controlled trial.

Feasibility and preliminary efficacy of the 'HEYMAN' healthy lifestyle program for young men: a pilot randomised controlled trial.
复制标题

DOI:
10.1186/s12937-017-0227-8
复制
发表时间:
2017-01-13
期刊:
影响因子:
5.4
通讯作者:
Collins CE
Collins CE
中科院分区:
医学2区
文献类型:
--
作者:
Ashton LM;Morgan PJ;Hutchesson MJ;Rollo ME;Collins CE

文献摘要

被引文献

相似文献

对于年轻男性来说,不健康的生活方式可能会损害他们的身体和/或心理健康,并使他们在成年后走上负面的健康轨道。尽管如此,仍缺乏证据来指导针对年轻男性制定有效的健康行为改变干预措施。这项研究评估了针对年轻男性的“HEYMAN”(利用电子健康来增强年轻男性的心理健康、活动和营养)健康生活方式计划的可行性和初步效果。一项试验性随机对照试验,将 50 名 18-25 岁的年轻男性随机分配到 HEYMAN 干预组 (n = 26) 或候补名单对照 (n = 24)。 HEYMAN 是一项为期 3 个月的干预措施,针对年轻男性,旨在改善饮食习惯、活动水平和幸福感。干预措施的制定是通过参与性研究模型(PRECEDE-PROCEED)进行的。干预措施包括电子健康支持(网站、可穿戴设备、Facebook 支持小组)、面对面会议(团体和个人)、个性化食物和营养报告、家庭阻力训练设备和份量控制工具。结果包括:研究程序(招募、随机化、数据收集和保留)和干预组成部分的可行性。广义线性混合模型估计了 3 个月时主要结局的治疗效果:每日计步步数、饮食质量、幸福感和几个次要结局。招募 50 名年轻人需要 7 周的招募期。干预后 3 个月的保留率达到 94%。保留的干预参与者(n = 24)表现出对大多数项目组件的合理使用水平,并报告了项目组件在吸引力、理解性、可用性、支持、满意度和说服能力方面的可接受水平,得分范围为 3.0 至 4.6(最多 5 分)。对于每日步数(1012.7,95% CI = −506.2、2531.6,p = 0.191,d = 0.36)、饮食质量评分(3.6、95% CI = −0.4、7.6、 p = 0.081, d = 0.48) 或总幸福感得分 (0.4, 95% CI = −1.6, 2.5, p = 0.683,d = 0.11)。日常蔬菜份量、能量密集、营养不良的食物、MVPA、体重、BMI、脂肪量、腰围和胆固醇有显着的干预效果(所有 p<0.05)。 HEYMAN 计划证明了帮助年轻人做出积极生活方式改变的可行性。这为开展更大规模、功能齐全的随机对照试验提供了支持,但需要对研究程序和干预部分进行细微修改。澳大利亚新西兰临床试验注册中心 ACTRN12616000350426。本文的在线版本 (doi:10.1186/s12937-017-0227-8) 包含补充材料,可供授权用户使用。
In young men, unhealthy lifestyle behaviours can be detrimental to their physical and/or mental health and set them on a negative health trajectory into adulthood. Despite this, there is a lack of evidence to guide development of effective health behaviour change interventions for young men. This study assessed the feasibility and preliminary efficacy of the ‘HEYMAN’ (Harnessing Ehealth to enhance Young men’s Mental health, Activity and Nutrition) healthy lifestyle program for young men. A pilot RCT with 50 young men aged 18–25 years randomised to the HEYMAN intervention (n = 26) or waitlist control (n = 24). HEYMAN was a 3-month intervention, targeted for young men to improve eating habits, activity levels and well-being. Intervention development was informed by a participatory research model (PRECEDE-PROCEED). Intervention components included eHealth support (website, wearable device, Facebook support group), face-to-face sessions (group and individual), a personalised food and nutrient report, home-based resistance training equipment and a portion control tool. Outcomes included: feasibility of research procedures (recruitment, randomisation, data collection and retention) and of intervention components. Generalized linear mixed models estimated the treatment effect at 3-months for the primary outcomes: pedometer steps/day, diet quality, well-being and several secondary outcomes. A 7-week recruitment period was required to enrol 50 young men. A retention rate of 94% was achieved at 3-months post-intervention. Retained intervention participants (n = 24) demonstrated reasonable usage levels for most program components and also reported reasonable levels of program component acceptability for attractiveness, comprehension, usability, support, satisfaction and ability to persuade, with scores ranging from 3.0 to 4.6 (maximum 5). No significant intervention effects were observed for the primary outcomes of steps/day (1012.7, 95% CI = −506.2, 2531.6, p = 0.191, d = 0.36), diet quality score (3.6, 95% CI = −0.4, 7.6, p = 0.081, d = 0.48) or total well-being score (0.4, 95% CI = −1.6, 2.5, p = 0.683, d = 0.11). Significant intervention effects were found for daily vegetable servings, energy-dense, nutrient-poor foods, MVPA, weight, BMI, fat mass, waist circumference and cholesterol (all p < 0.05). The HEYMAN program demonstrated feasibility in assisting young men to make some positive lifestyle changes. This provides support for the conduct of a larger, fully-powered RCT, but with minor amendments to research procedures and intervention components required. Australian New Zealand Clinical Trials Registry ACTRN12616000350426. The online version of this article (doi:10.1186/s12937-017-0227-8) contains supplementary material, which is available to authorized users.